Watch For GI Effects in Roflumilast Patients

New data will help clarify when to use roflumilast (Daliresp) to prevent COPD exacerbations.

You may hear that roflumilast decreases hospitalizations due to COPD exacerbations by 25%. But this is a relative reduction. Let your team know that this works out to one fewer hospitalization for every 24 severe COPD patients on Daliresp for a year.

Continue to maximize bronchodilators and inhaled steroids first. Ensure that patients are using their inhalers properly and consistently.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals